MannKind Corporation
MannKind Corporation (MNKD) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · MNKD · as of Jun 8, 2026
Key Statistics
Explore MannKind Corporation Data
mnkd stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 19 · Buy rate: 47.4%
The MNKD analyst consensus is Buy, based on ratings from 19 Wall Street analysts over the past 3 months. The average 12-month price target is $8.50, representing +150.74% upside from the current price of $3.39.
Competitors & Peers
mnkd competitorsMNKD
ABCL
AUPH
BHVN
CLDX
HRMYStock Performance
Full HistoryAbout MannKind Corporation
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine …
what is mannkind corporation · mnkd stock overview · mannkind corporation company profile · who is mannkind corporation ceo · mnkd NASDAQ · mannkind corporation headquarters · mannkind corporation business segments
About Stock Overview & Key Data
MannKind Corporation (MNKD) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 28, 2004. As of the latest trading session, MNKD stock price is $3.39, with a market capitalization of $1.0B. The stock has returned -21.42% over the past 12 months and -39.44% year-to-date.
According to 19 Wall Street analysts, the consensus rating for MannKind Corporation stock is Buy, with an average 12-month price target of $8.50. In fiscal year 2025, MannKind Corporation reported revenue of $349.0M and net income of $5.9M. For detailed data — including MannKind Corporation revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, MannKind Corporation (MNKD) stock price is $3.39. The stock is traded on NASDAQ under the ticker symbol MNKD. The 52-week range is $2.23 – $6.51.